182 related articles for article (PubMed ID: 35715667)
1. Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2 + breast cancer.
Id Said B; Chen H; Jerzak KJ; Warner E; Myrehaug S; Tseng CL; Detsky J; Husain Z; Sahgal A; Soliman H
J Neurooncol; 2022 Aug; 159(1):177-183. PubMed ID: 35715667
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
Mills MN; Walker C; Thawani C; Naz A; Figura NB; Kushchayev S; Etame A; Yu HM; Robinson TJ; Liu J; Vogelbaum MA; Forsyth PA; Czerniecki BJ; Soliman HH; Han HS; Ahmed KA
BMC Cancer; 2021 Mar; 21(1):223. PubMed ID: 33663447
[TBL] [Abstract][Full Text] [Related]
3. Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4.
Stumpf PK; Cittelly DM; Robin TP; Carlson JA; Stuhr KA; Contreras-Zarate MJ; Lai S; Ormond DR; Rusthoven CG; Gaspar LE; Rabinovitch R; Kavanagh BD; Liu A; Diamond JR; Kabos P; Fisher CM
Clin Cancer Res; 2019 Jul; 25(13):3946-3953. PubMed ID: 30940654
[TBL] [Abstract][Full Text] [Related]
4. Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases.
Mitsuya K; Watanabe J; Nakasu Y; Hayashi N; Harada H; Ito I
BMC Cancer; 2016 Jul; 16():391. PubMed ID: 27377061
[TBL] [Abstract][Full Text] [Related]
5. Incidence of radionecrosis in single-fraction radiosurgery compared with fractionated radiotherapy in the treatment of brain metastasis.
Donovan EK; Parpia S; Greenspoon JN
Curr Oncol; 2019 Jun; 26(3):e328-e333. PubMed ID: 31285676
[TBL] [Abstract][Full Text] [Related]
6. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.
Bellon JR; Tayob N; Yang DD; Tralins J; Dang CT; Isakoff SJ; DeMeo M; Burstein HJ; Partridge AH; Winer EP; Krop IE; Tolaney SM
Int J Radiat Oncol Biol Phys; 2022 May; 113(1):117-124. PubMed ID: 34990776
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
Montemurro F; Delaloge S; Barrios CH; Wuerstlein R; Anton A; Brain E; Hatschek T; Kelly CM; Peña-Murillo C; Yilmaz M; Donica M; Ellis P
Ann Oncol; 2020 Oct; 31(10):1350-1358. PubMed ID: 32634611
[TBL] [Abstract][Full Text] [Related]
10. Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
Okines A; Irfan T; Khabra K; Smith I; O'Brien M; Parton M; Noble J; Stanway S; Somaiah N; Ring A; Johnston S; Turner N
Breast J; 2018 May; 24(3):253-259. PubMed ID: 28833867
[TBL] [Abstract][Full Text] [Related]
11. Single-fraction radiosurgery versus fractionated stereotactic radiotherapy in patients with brain metastases: a comparative study.
Loo M; Pin Y; Thierry A; Clavier JB
Clin Exp Metastasis; 2020 Jun; 37(3):425-434. PubMed ID: 32185576
[TBL] [Abstract][Full Text] [Related]
12. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated stereotactic radiosurgery (HSRS) as a salvage treatment for brain metastases failing prior stereotactic radiosurgery (SRS).
Yan M; Lee M; Myrehaug S; Tseng CL; Detsky J; Chen H; Das S; Yeboah C; Lipsman N; Costa LD; Holden L; Heyn C; Maralani P; Ruschin M; Sahgal A; Soliman H
J Neurooncol; 2023 Mar; 162(1):119-128. PubMed ID: 36914878
[TBL] [Abstract][Full Text] [Related]
15. Progressively Enlarging Cerebellar Hematoma Concurrent with T-DM1 Treatment.
Vilela MD; Longstreth WT; Pedrosa HAS; Gil GOB; Duarte JM; Filho MAD
World Neurosurg; 2018 Mar; 111():109-114. PubMed ID: 29274446
[TBL] [Abstract][Full Text] [Related]
16. Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer.
Moraes FY; Mansouri A; Dasgupta A; Ramotar M; Kosyak N; Weiss J; Laperriere N; Millar BA; Berlin A; Conrad T; van Prooijen M; Heaton R; Coolens C; Winter J; Bernstein M; Zadeh G; Kongkham P; Doherty M; Shultz DB
Lung Cancer; 2021 May; 155():34-39. PubMed ID: 33721614
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
18. Radionecrosis (RN) in patients with brain metastases treated with stereotactic radiosurgery (SRS) and immunotherapy.
Andring L; Squires B; Seymour Z; Fahim D; Jacob J; Ye H; Marvin K; Grills I
Int J Neurosci; 2023 Feb; 133(2):186-193. PubMed ID: 33685315
[TBL] [Abstract][Full Text] [Related]
19. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery.
Blonigen BJ; Steinmetz RD; Levin L; Lamba MA; Warnick RE; Breneman JC
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):996-1001. PubMed ID: 19783374
[TBL] [Abstract][Full Text] [Related]
20. Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain.
Milano MT; Grimm J; Niemierko A; Soltys SG; Moiseenko V; Redmond KJ; Yorke E; Sahgal A; Xue J; Mahadevan A; Muacevic A; Marks LB; Kleinberg LR
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):68-86. PubMed ID: 32921513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
